Clinical trials: Sirolimus, completed
Prostate Cancer Metastatic
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.
- Trial name
- NCT02407054
- Testing
- LY3023414, Enzalutamide
- Where
- 36 sites in United States
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Peripheral Arterial Disease
The ILLUMINA Study. (ILLUMINA)
The aim of the prospective, multicentre, single-arm study is to assess safety and efficacy of a drug eluting stent in Nitinol alloy (NiTiDES) in term of vessel patency and composite event-free survival rate up to two years…
- Trial name
- ILLUMINA (NCT03510676)
- Testing
- NiTiDES
- Where
- 10 sites in France, Germany and 1 more
- Volunteers
- 100 people
- Sponsor
- CID - Carbostent & Implantable Devices
Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
This randomized phase II trial is studying how well giving selumetinib together with or without temsirolimus works in treating patients with metastatic, recurrent, or locally advanced soft tissue sarcoma that cannot be removed by…
- Conditions
- Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT01206140
- Testing
- Laboratory Biomarker Analysis, Selumetinib, Temsirolimus
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Glioma of Brain
A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
In the proposed trial, patients will be administered ribociclib+everolimus prior to surgical resection of their tumor. Recurrent GBM patients will be randomized into one of the three time-interval cohorts for the first two dose…
- Trial name
- NCT03834740
- Testing
- Ribociclib, Everolimus
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Sarcoma
Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
The purpose of this study is to identify a safe dosing regimen for the combination of Torisel and liposomal doxorubicin in patients with recurrent sarcoma.
- Trial name
- NCT00949325
- Testing
- temsirolimus plus liposomal doxorubicin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Scleritis
Sirolimus Injections for Autoimmune Scleritis
Background: Autoimmune scleritis is an inflammatory disease that affects the white outer part of the eye. It is associated with immune system disorders like rheumatoid arthritis. It can cause blindness in severe cases.
- Trial name
- ISAS (NCT01517074)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Advanced Cancer, Metastatic Cancer
Rapamycin Plus Bevacizumab in Advanced Cancers
The goal of this trial is to determine the toxicity and maximum dose of rapamycin and bevacizumab given together to subjects with advanced cancers.
- Trial name
- NCT00667485
- Testing
- Rapamycin (liquid), Bevacizumab, Rapamycin (Tablets)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Chicago
Hormone Refractory Prostate Cancer
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
The purpose of this study is to determine the biochemical response rate (PSA) to single agent RAD001 in patients with metastatic hormone-refractory prostate cancer (HRPC).
- Trial name
- NCT00629525
- Testing
- RAD001
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Daniel George, MD
De Novo Renal Transplantation
Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients
To evaluate the safety and tolerability of early switch to everolimus from cyclosporine A in de novo renal transplant recipients by assessing rejection rate everolimus trough levels, other safety laboratory variables and adverse…
- Trial name
- NCT00464399
- Testing
- everolimus
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis
Prospective, multi-center, randomized 1:1, single blind trial using BuMA Supreme versus Resolute Integrity conducted in approximately 14 interventional cardiology centers in The Netherlands, Belgium, Spain and Portugal.
- Trial name
- NCT02236975
- Testing
- BuMA Supreme Biodegradable drug coating coronary stent system, Resolute Integrity durable polymer stent system
- Where
- 12 sites in Belgium, Netherlands and 2 more
- Volunteers
- 168 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Metastatic Clear Cell Renal Cancer
Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer
When kidney cancer spreads beyond the kidney, it is known as metastatic kidney cancer. This is very difficult to treat and almost all patients will die of their disease within 3 years.
- Trial name
- DEVELOP (NCT01714765)
- Testing
- Dovitinib, Everolimus
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Queen Mary University of London
Adult Glioblastoma, Adult Gliosarcoma
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
This phase I/II trial studies the side effects and best dose of temsirolimus when given together with sorafenib tosylate and to see how well they work in treating patients with glioblastoma that has come back.
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00329719
- Testing
- Conventional Surgery, Laboratory Biomarker Analysis, Sorafenib Tosylate
- Where
- 190 sites in United States
- Volunteers
- 115 people
- Sponsor
- National Cancer Institute (NCI)
Facial Angiofibroma, Tuberous Sclerosis
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
The study aims to compare the safety and efficacy of two different strengths of Rapamycin cream, topical and placebo over 26 weeks in the treatment of facial angiofibroma (FA) associated with Tuberous Sclerosis Complex (TSC).
- Trial name
- NCT03826628
- Testing
- rapamycin
- Where
- 17 sites in United States, Australia and 7 more
- Volunteers
- 107 people
- Sponsor
- Dermatology Specialties Limited Partnership
Peripheral Vascular Disease
The DESappear Study: Drug Eluting Scaffold
The aim of this study is to prospectively collect information to evaluate the safety and performance of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral scaffold system for the treatment of symptomatic primary…
- Trial name
- DESappear (NCT02869087)
- Testing
- Akesys Prava Scaffold
- Where
- 11 sites in Austria, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Elixir Medical Corporation
Renal Transplantation
Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic
The purpose of this study is to determine whether the combination of Myfortic and sirolimus is effective at preventing rejection while preserving kidney function in stable kidney transplant recipients.
- Trial name
- MYFIIRP (NCT00713284)
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- California Pacific Medical Center Research Institute
Heart Transplantation
SCHEDULE Follow Up Visit 5-7 yr
The major aim of this extension study was to evaluate the long-term effect (i.e. 5 to 7 years) of early initiation of everolimus and early elimination of CsA compared to standard immunosuppressive regimen including CsA on primary…
- Trial name
- CRAD001ANO05 (NCT02864706)
- Testing
- Everolimus, Cyclosporine, Mycophenolate mofetil
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
A Multi-center Post-Market Surveillance Registry
This multicenter, prospective, observational registry will evaluate the safety and performance of the CYPHER SELECT™ Sirolimus-eluting Coronary Stent, and of all future generation of commercially approved Cordis Sirolimus-eluting…
- Trial name
- E-SELECT (NCT00438919)
- Testing
- drug-eluting stent
- Where
- Switzerland
- Volunteers
- 15,000 people
- Sponsor
- Cordis US Corp.
Renal Transplant
Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction
The purpose of this study is to evaluate whether conversion to everolimus (Zortress®), allowing the elimination or reduction of calcineurin inhibitors, will reduce nephrotoxicity (measured by increased creatinine clearance) and…
- Trial name
- NCT01935128
- Testing
- Arm 1 Everolimus/Reduced dose tacrolimus
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Toledo Health Science Campus
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
This phase I trial is studying the side effects and best dose of temsirolimus when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00316849
- Testing
- pharmacological study, adjuvant therapy, 3-dimensional conformal radiation therapy
- Where
- 11 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Sirolimus in Treating Patients With Glioblastoma Multiforme
RATIONALE: Chemotherapy drugs such as sirolimus use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00047073
- Testing
- Rapamycin, Surgery, Supportive Care
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jonsson Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.